News Sentiment

CHRS sentiment intelligence

Coherus BioSciences Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 72 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.54 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

78/100 classification confidence.

Company focus 63

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend inactive

+6.2% over one week, +10.0% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

What's Driving Junshi Biosciences' Recent Momentum

Market Reaction

Price moving ahead of tone

60/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 78/100 classification
One-week reaction 6.2% Price confirming higher
Trend fit Trend inactive 10.0% over four weeks
Fair value -15.1% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 15
Neutral 51
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 63
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
Stock Titan 11
Investing.com 6
TradingKey 5
TradingView 3
GlobeNewswire 3
simplywall.st 3
AD HOC NEWS 2

Event Lens

What the news is about

Classified themes
Market update 35
Earnings 29
Deals and strategy 4
Macro sensitivity 3
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 72
Investing.com Direct company coverage

Earnings call transcript: Coherus BioSciences Q1 2026 revenue misses forecast

Coherus BioSciences reported Q1 2026 revenue of $12.31 million, falling short of the $14.43 million forecast, but its EPS of -$0.25 met expectations. Despite the revenue miss, the company's shares rose 11.43% in after-hours trading, driven by investor optimism about future growth

Tone
Neutral 50/100
Event
Earnings
Published
12 May 2026 14:08
Source
Investing.com
TradingKey Direct company coverage

Coherus BioSciences Inc CHRS

This page provides an overview of Coherus BioSciences Inc. (CHRS) stock, including its current price, market cap, and P/E ratio. It shows the stock closed at $1.950 with an 11.43% increase on May 11th. The platform also offers various financial analysis tools and news for investo

Tone
Positive 65/100
Event
Market update
Published
12 May 2026 02:39
Source
TradingKey
GuruFocus Direct company coverage

Coherus (CHRS) Reports Q1 Revenue Below Expectations

Coherus BioSciences (CHRS) announced Q1 revenue of $12.31 million, falling short of the anticipated $14.34 million. The company, which has a GF Score™ of 51/100, is focusing on its LOQTORZI product for neuroendocrine prostate cancer and other pipeline products, despite facing cha

Tone
Negative 30/100
Event
Earnings
Published
12 May 2026 00:39
Source
GuruFocus
Stock Titan Direct company coverage

Coherus Oncology (CHRS) grows Q1 2026 revenue as losses narrow and cash hits $167M

Coherus Oncology reported a notable increase in Q1 2026 revenue to $12.3 million from $7.6 million year-over-year, primarily driven by LOQTORZI sales totaling $11.8 million. The company successfully narrowed its GAAP net loss from continuing operations to $36.9 million and mainta

Tone
Positive 67/100
Event
Earnings
Published
11 May 2026 20:38
Source
Stock Titan
24/7 Wall St. Direct company coverage

Coherus Biosciences Inc (CHRS) Stock News & Articles

This page provides an overview of Coherus BioSciences Inc (CHRS), a biopharmaceutical company specializing in biosimilars and immuno-oncology treatments. It details the company's key products like UDENYCA, CIMERLI, and YUSIMRY, and highlights its strategic partnerships aimed at a

Tone
Positive 64/100
Event
Market update
Published
11 May 2026 11:38
Source
24/7 Wall St.
GlobeNewswire Direct company coverage

Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026

Coherus Oncology, Inc. announced it will release its first quarter 2026 financial results after market close on Monday, May 11, 2026. The company's management will host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a business update. A

Tone
Neutral 50/100
Event
Earnings
Published
05 May 2026 11:09
Source
GlobeNewswire
Stock Titan Direct company coverage

Satterfield reports 6.93M shares in Coherus Oncology (NASDAQ: CHRS) ownership filing

Thomas A. Satterfield, Jr. has filed a Schedule 13G/A, reporting beneficial ownership of 6.93 million shares, or 4.6%, of Coherus Oncology (NASDAQ: CHRS) common stock. This includes shares held jointly, through various entities he controls, and via limited powers of attorney for

Tone
Neutral 50/100
Event
Market update
Published
30 Apr 2026 08:09
Source
Stock Titan